



(11) **EP 2 460 820 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
C07K 14/01 ^(2006.01) **A61K 39/12** ^(2006.01)
C12N 7/04 ^(2006.01) **C12Q 1/68** ^(2018.01)
A61K 39/295 ^(2006.01)

(48) Corrigendum issued on:
19.06.2019 Bulletin 2019/25

(45) Date of publication and mention
of the grant of the patent:
10.04.2019 Bulletin 2019/15

(21) Application number: **12155382.0**

(22) Date of filing: **29.12.2005**

(54) **PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS**

IMMUNOGENE PCV2-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR HERSTELLUNG
SOLCHER ZUSAMMENSETZUNGEN

COMPOSITIONS IMMUNOGÈNES PCV2 ET PROCÉDÉS DE PRODUCTION DE CES
COMPOSITIONS

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI
SK TR**
Designated Extension States:
BA HR MK

(30) Priority: **30.12.2004 US 640510 P**
13.01.2005 US 34797
29.12.2005 US 319975

(43) Date of publication of application:
06.06.2012 Bulletin 2012/23

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
05856068.1 / 1 833 992

(73) Proprietor: **Boehringer Ingelheim Animal Health
USA Inc.**
Duluth, GA 30096 (US)

(72) Inventors:
• **Eichmeyer, Mark**
St. Joseph, MO 64506-2002 (US)

• **Nitzel, Greg**
St. Joseph, MO 64506-2002 (US)
• **Schaeffer, Merrill**
St. Joseph, MO 64506-2002 (US)

(74) Representative: **Hoffmann Eitle**
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München (DE)

(56) References cited:
WO-A1-2007/028823 WO-A2-00/01409
WO-A2-00/77216 WO-A2-2005/009462

• **BLANCHARD P ET AL: "Protection of swine
against post-weaning multisystemic wasting
syndrome (PMWS) by porcine circovirus type 2
(PCV2) proteins", VACCINE, ELSEVIER LTD, GB,
vol. 21, no. 31, 7 November 2003 (2003-11-07),
pages 4565-4575, XP004467337, ISSN:
0264-410X, DOI: 10.1016/S0264-410X(03)00503-6**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 460 820 B8

- NAWAGITGUL P ET AL: "Open reading frame 2 of porcine circovirus type 2 encodes a major capsid protein", JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, SPENCERS WOOD, GB, vol. 81, no. 9, 1 January 2000 (2000-01-01), pages 2281-2287, XP002978778, ISSN: 0022-1317
- KIM YUNA ET AL: "Characterization of the recombinant proteins of porcine circovirus type2 field isolate expressed in the baculovirus system", JOURNAL OF VETERINARY SCIENCE, KOREAN SOCIETY OF VETERINARY SCIENCE, SUWON, KR, vol. 3, no. 1, 1 March 2002 (2002-03-01), pages 19-23, XP002349036, ISSN: 1229-845X
- KIXMOLLER M ET AL: "Reduction of PMWS-associated clinical signs and co-infections by vaccination against PCV2", VACCINE, ELSEVIER LTD, GB, vol. 26, no. 27-28, 25 June 2008 (2008-06-25), pages 3443-3451, XP022710551, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2008.04.032 [retrieved on 2008-05-05]
- FACHINGER ET AL: "The effect of vaccination against porcine circovirus type 2 in pigs suffering from porcine respiratory disease complex", VACCINE, ELSEVIER LTD, GB, vol. 26, no. 11, 1 March 2008 (2008-03-01) , pages 1488-1499, XP022505432, ISSN: 0264-410X